BRCA1 and breast carcinoma: Multi-gene testing and expanded panel testing of all breast cancer patients could increase the detection rate of pathogenic variants compared to testing for BRCA1/2 alone and may have a potential clinical impact for patients and their families in terms of targeted treatment and prevention strategies.